Abstract: In certain embodiments, the invention includes therapeutic methods of using a BTK inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.

Abstract: Systems and methods for measuring turbulent gas flux using high-speed vertical wind speed measurements (e.g., on the order of 5-10 Hz or more frequently) and low-speed gas content measurements (e.g., on the order of 5 Hz or less frequently), without the need for the sophisticated and expensive high-speed hardware to separate gas samples (e.g., into accumulation bags) according to updrafts and downdrafts. A time series of high-speed vertical wind speed data is used as a guide to distinguish between updrafts and downdrafts. When vertical wind speed is upward (updraft), the low-speed gas content is recorded into a data structure in one location, or marked with one flag. When vertical wind speed is downward (downdraft), the low-speed gas content is recorded into a different location, or marked with a different flag. Eddy Accumulation or Relaxed Eddy Accumulation computations can be performed using the stored gas content data to determine gas flux.

Abstract: Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms (PI3K-?,?, PI3K-?, and PI3K-?, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-? inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-?, and BTK inhibitor.

Abstract: Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms (PI3K-?,?, PI3K-?, and PI3K-?), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-? inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.

Abstract: Systems and methods for measuring turbulent gas flux using high-speed vertical wind speed measurements (e.g., on the order of 5-10 Hz or more frequently) and low-speed gas content measurements (e.g., on the order of 5 Hz or less frequently), without the need for the sophisticated and expensive high-speed hardware to separate gas samples (e.g., into accumulation bags) according to updrafts and downdrafts. A time series of high-speed vertical wind speed data is used as a guide to distinguish between updrafts and downdrafts. When vertical wind speed is upward (updraft), the low-speed gas content is recorded into a data structure in one location, or marked with one flag. When vertical wind speed is downward (downdraft), the low-speed gas content is recorded into a different location, or marked with a different flag. Eddy Accumulation or Relaxed Eddy Accumulation computations can be performed using the stored gas content data to determine gas flux.

Abstract: Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-?inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-? inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

Abstract: Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-? inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-? inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

Abstract: In some embodiments, the invention includes a therapeutic combination of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms, and a Bruton's tyrosine kinase (BTK) inhibitor. In some embodiments, the invention includes therapeutic methods of using a BTK inhibitor and a PI3K-? inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.

Abstract: Therapeutic compositions and methods of using the compositions, including combinations of a Bruton's tyrosine kinase (BTK) inhibitor, a phosphomositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both y- and ?-isoforms (PI3K-?,?, PI3K-?, and PI3K-?, a programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor, and/or a Janus kinase-2 (JAK-2) inhibitor are described. In certain embodiments, the invention includes therapeutic methods of using a PD-1 monoclonal antibody and a BTK inhibitor. In other embodiments, the invention includes therapeutic methods of using a PD-L1 monoclonal antibody and a BTK inhibitor. In other embodiments, the invention includes therapeutic methods of using a PD-1 inhibitor, a BTK inhibitor, and a PI3K˜? inhibitor. In other embodiments, the invention includes therapeutic methods of using a PD-L1 inhibitor, a BTK inhibitor, and a PI3K˜? inhibitor.

Abstract: Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms (PI3K-?,?, PI3K-?, and PI3K-?), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-? inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.

Abstract: In certain embodiments, the invention includes therapeutic methods of using a BTK inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.

Abstract: Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms (PI3K-?,?, PI3K-?, and PI3K-?, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-? inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-?, and BTK inhibitor.

Abstract: In an embodiment, therapeutic methods and uses of Bruton's Tyrosine Kinase (BTK) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for a BTK inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described.

Abstract: Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-? inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-? inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

Abstract: Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody.

Abstract: An embodiment is directed to a method for limiting network communications. The method is implemented at a device through which communications can be routed between client devices and the internet. The method includes receiving a routable communication. A communication type for the routable communication is identified. The communication type may be owner, authorized, or anonymous. Access rules for the identified communication type are identified. The routing of the communication is limited according to the identified access rules.

Abstract: An embodiment is directed to a method for limiting network communications. The method is implemented at a device through which communications can be routed between client devices and the internet. The method includes receiving a routable communication. A communication type for the routable communication is identified. The communication type may be owner, authorized, or anonymous. Access rules for the identified communication type are identified. The routing of the communication is limited according to the identified access rules.

Abstract: A computer readable medium comprises executable instructions to: provide an SDK to a client computer comprising executable instructions for communicating with a build server, receive an HTML/Javascript source application and a configuration file referencing one or more source application files over a computer network from a client computer to the build server, transmit the HTML/Javascript source application and configuration file to multiple compile servers corresponding to each of multiple mobile device platforms, combine the HTML/Javascript source application with a mobile device platform specific framework source code for each mobile device platform on each compile server, compile the HTML/Javascript source application and framework source code on the compile server to output an executable native application for each mobile device platform, and transmit each executable native application from the compile server to the client computer over a computer network.

Abstract: Systems and methods for measuring turbulent gas flux using high-speed vertical wind speed measurements (e.g., on the order of 5-10 Hz or more frequently) and low-speed gas content measurements (e.g., on the order of 5 Hz or less frequently), without the need for the sophisticated and expensive high-speed hardware to separate gas samples (e.g., into accumulation bags) according to updrafts and downdrafts. A time series of high-speed vertical wind speed data is used as a guide to distinguish between updrafts and downdrafts. When vertical wind speed is upward (updraft), the low-speed gas content is recorded into a data structure in one location, or marked with one flag. When vertical wind speed is downward (downdraft), the low-speed gas content is recorded into a different location, or marked with a different flag. Eddy Accumulation or Relaxed Eddy Accumulation computations can be performed using the stored gas content data to determine gas flux.